Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 31, 2025
Daily News
October 31, 2025
- Health Minister Vows to Balance Public Burden, Innovation, and Supply in FY2026 Revision
October 31, 2025
- Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
October 31, 2025
- Boehringer Bags Rights to Kyowa Kirin’s Preclinical Autoimmune Program
October 31, 2025
- Espha’s Velcade AG Wins Approval for Mantle Cell Lymphoma
October 31, 2025
- MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
- Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
- Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
October 31, 2025
- Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
- Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
- Leqembi’s April-September Sales at 41.1 Billion Yen: Eisai
October 31, 2025
- TMS Founder Sees “Ray of Hope” in Novel Stroke Drug TMS-007
October 31, 2025
- The Unseen Edge & the Shadow of Bias: Awareness as the Cornerstone of Leadership Success
October 31, 2025
- Jardiance Dominates September Detailing Rankings with Five Wins: Intage
October 31, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…